Background
==========

The increasing complexity of lymphoma diagnosis and classification is the result of a vastly improved understanding of its underlying molecular pathogenesis and resultant attempts to group subtypes of lymphoma in a clinically and biologically meaningful manner. From a practical perspective, this increasing complexity places great demands on the pathologist. Accurate diagnosis and classification of lymphoma in lymph node biopsies requires pathological evaluation utilising morphological analysis of an acceptable biopsy specimen, together with a series of supplementary tests including immunophenotyping by immunohistochemistry and flow cytometry, and increasingly cytogenetics, FISH and PCR data \[[@B1]\]. Such ancillary tests can be costly and time consuming, requiring specialised technicians and analytical experience from multiple divisions of a pathology laboratory. Of benefit would be a cost-effective, single platform ancillary test that provides a rapid standardised diagnosis of lymphoma and recognition of major subtypes, allowing more selective use of other ancillary tests during subsequent assessment by the pathologist.

Genome-wide gene expression profiling (GEP) is a novel approach to disease classification based on the molecular biology of the disease. This \'genetic fingerprint\' data thus allows the identification and classification of individual tissue samples according to their distinct gene expression profiles. There is a significant body of research employing GEP in lymphoma, having been used for a number of purposes including distinguishing closely related lymphoma phenotypes such as diffuse large B-Cell lymphoma (DLBCL) versus Burkitt lymphoma \[[@B2]\] and DLBCL from primary mediastinal B-cell lymphoma \[[@B3]\], to trace malignant lymphoma phenotypes to \"normal cell of origin\" \[[@B4]\] and to identify expression profiles linked to tumour prognosis \[[@B5]\]. However, there is a lack of publications that address the potential value of gene expression microarray in aiding the routine diagnosis and classification of lymphoma in tissue biopsies from individual cases suspected of lymphoma. The feasibility of GEP as a tool to classify tumour tissue has been examined for other cancers, such as breast \[[@B6]\], colon \[[@B7]\], prostate \[[@B8]\] and renal tumours \[[@B9]\].

Distinct from previous microarray studies of lymphoma, this single institute study evaluated whether gene expression microarray as a single platform could be used to distinguish three major subtypes of lymphoma and non-malignant reactive lymphadenopathy (RL) in individual lymph node samples. To our knowledge, this study is a first attempt to apply such a strategy to lymph node specimens across different subtype diagnoses in a diagnostic setting. Our heterogeneous study set enabled the identification of gene signatures that are likely an accurate representation of each diagnostic type, given that this was determined by comparing each diagnostic type against the remaining cases by binary classification approach.

Methods
=======

Patient samples
---------------

Lymph node specimens from patients undergoing biopsy for suspected lymphoma were identified by the Department of Pathology at St Vincent\'s Hospital, Sydney. Samples were collected subject to written consent for this human research ethics approved study (H00/028/1). A portion of the fresh biopsy specimen (≥2 mm^3^) was collected in RNAlater solution (Ambion, Foster City, CA) and then cryopreserved in liquid nitrogen. A further five biopsy samples (two cHL, two DLBCL, one FL) were obtained from the Newcastle Mater Misericordiae Hospital. The diagnosis and classification of each specimen was made or reviewed by an expert haematopathologist (JT) practising at our centre \[[@B10]\], according to the WHO Classification of Tumours of Haematopoietic and Lymphoid tissue 2001 \[[@B11]\]. All samples were collected during 2001-07 and analysed prior to the 2008 update of this classification system. Most cases (*n*= 16) of DLBCL were subclassified into germinal centre B (GCB) and non-GCB cell types (*n*= 5 and *n=*11 respectively) by immunohistochemistry according to the Hans algorithm \[[@B12]\]. The 23 cases of RL included reactive hyperplasia (*n*= 16), reactive hyperplasia with progressive germinal centre transformation (*n*= 3) or granuloma related to toxoplasmosis (*n*= 1), dermatopathic lymphadenitis (*n*= 1) and normal (*n*= 2).

RNA and Microarray assays
-------------------------

Frozen lymph node tissue was homogenised in TRIzol reagent (Invitrogen, Victoria, Australia) using a pellet pestle and total RNA isolated using RNeasy micro-column purification (Qiagen, Doncaster, Australia). The integrity of total RNA was assessed by denaturing agarose gel electrophoresis (1% agarose, 221 mM formaldehyde, 20 mM MOPS, 5 mM sodium acetate, 1 mM EDTA). Only samples with distinct 28 S and 18 S RNA bands were assayed by microarray. The total RNA extracted from granulocyte colony-stimulating factor mobilised peripheral blood stem cells (PBSC) samples from 10 healthy individuals (collected with informed consent) were pooled and used as the reference RNA for microarray assays. Two-colour fluorescent probe synthesis was carried out on 2 μg of patient (Cy5 - Red) and reference (Cy3 - Green) RNA and then competitively hybridised to a microarray using the 3DNA 900MPX kit (Genisphere, Hatfield, PA) according to the manufacturer\'s protocol. A GenePix 4000A scanner and GenePix Pro 3.0 image analysis software (Molecular devices, Sunnyvale, CA) was used to capture microarray images and quantify fluorescent signals from each feature. The microarrays used in this study were printed by the Adelaide Microarray Facility (Adelaide, Australia) using the Compugen library of 19000 70-mer oligonucleotides, which covers over 12000 generic human genes.

Preprocessing of array data
---------------------------

Data from GenePix result files were pre-processed by within-array print-tip Lowess normalisation. The quality of each array was assessed prior to analysis to ensure only arrays of sufficient quality were retained. A quality score was obtained using the QC CV scoring from arrayQuality \[[@B13]\]. The microarray data with clinical information have been deposited in NCBI\'s Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) and are accessible through GEO Series accession number GSE23647. This study is comprised from two batches of arrays developed over two years. The batches were analysed and normalised separately to maintain the independence of the two datasets.

GEP classification analysis
---------------------------

The statistical analysis was performed using the R statistical software version 2.8.1. Microarray gene expression data from 81 patients of batch-1 arrays (training set) were used to develop a diagnostic profile. An independent series consisting of a further 35 patients (batch-2 arrays - test set) were used to independently assess the classification accuracy of the profile. The patient information, diagnosis and number of samples used in the training and test dataset of this study are indicated in Table [1](#T1){ref-type="table"}.

###### 

Summary of the biopsies in each disease category examined by microarray

  ----------------------------------------------------------------------
                                Training set\   Test set\   Total\
                                (*n*= 81)       (*n*= 35)   (*n*= 116)
  ----------------------------- --------------- ----------- ------------
  **Patient characteristics**                               

   Male (%)                     64%             54%         

   Age range                    16-83           21-82       

   Median age                   53              56          

  **Diagnosis**                                             

   RL                           16              7           23

   cHL                          12              7           19

   NHL                          53              21          74

    DLBCL                       8               11          19

    FL                          25              10          35

    Other NHL\*                 20              0           20
  ----------------------------------------------------------------------

The table summarises the overall number of biopsies for each subtype examined and also the corresponding numbers divided into training and test sets for analysis.

\*Includes cases of Burkitt-like lymphoma, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukaemia, anaplastic large cell lymphoma, extranodal NK/T-cell lymphoma, and other T-cell lymphomas.

The ability of GEP to ascertain the correct diagnosis of each biopsy was assessed via diagonal linear discriminant analysis (DLDA) with classification error rates in the training set determined by leave one out cross-validation (LOOCV). The ratio of between sum of squares to within sum of squares (*bss/wss*) criteria was used for feature selection performed within each CV fold. As a measure of discriminative power in two-class classification, the selective use of features ranked high in *bss/wss*enriches for potential biomarkers of interest. The top ranked *bss/wss*genes ranging from 10-500 (increments of 10) were assessed within the classification development to identify the number of genes required to obtain a minimal (optimal) cross-validation error rate (see Additional file [1](#S1){ref-type="supplementary-material"}). The classification power of the determined optimal set of genes was then tested on the independent test set sample. Firstly, the results for each classification built from training datasets are expressed in terms of a classification accuracy rate (%), which represents the similarity between the pathological clinical diagnosis and the microarray diagnosis \[[@B14]\]. The accuracy rate of training datasets was determined by subtracting the LOOCV-error rate (%) from 100%. A separate dataset was then used to obtain independent error and accuracy rates. A DLDA classification rule was constructed from the complete training set data using the optimal number of genes estimated via the LOOCV stage of the analysis. This classification rule was then used to classify the independent data. The independent test dataset accuracy rate denotes the percentage of samples in the test dataset that have been correctly diagnosed using the molecular signatures identified from classification of the training dataset.

To examine the feasibility of GEP to classify RL versus lymphoma and subtypes of lymphoma, the expression data was analysed according to three different approaches:

1\. A global (all data) multi-class strategy was performed to classify the four main classes examined in this study (RL, cHL, FL and DLBCL) in a single step.

2\. A series of independent local (selected data) pair-wise (binary-class) comparisons of the four main classes examined was made. Comparisons included lymphoma versus RL, cHL versus NHL (inclusive of 3 and 17 cases respectively of rare T- and B cell lymphoma subtypes), and lastly, FL versus DLBCL, the two most prevalent forms of NHL in Caucasian populations \[[@B10]\]. These will be refered to as the \'local binary comparisons\'

3\. A number of \'global binary comparisons\' were performed by pair-wise comparisons of samples from an individual subtype versus the remaining data.

For all classification strategies, both LOOCV and independent test set accuracy rates were determined as mentioned above.

Heat maps
---------

Heat maps of the set of genes (classifiers) yielding the optimal LOOCV accuracy rates were produced. Clustering was performed for both samples and genes utilising hierarchical clustering with Euclidean distance as the dissimilarity function with complete linkage agglomeration. Dendrograms are displayed on the appropriate axis of the heat map.

Results
=======

Microarray analysis of lymph node biopsies
------------------------------------------

Microarrays quantifying gene expression in lymph node biopsies (*n*= 142) suspected of lymphoma were assessed for quality using the arrayQuality package. Arrays with a CV QC score of \>1 were identified as sub-optimal in quality and subsequently removed from analysis to result in a final total of 116 arrays analysed. A summary of the diagnosis of each of these biopsies and number of each subtype examined is shown in Table [1](#T1){ref-type="table"}.

A diagnostic profile for the global multi-class approach consisting of 50 genes was developed, and demonstrated an optimal LOOCV accuracy rate of 83.6% for the diagnosis of biopsies as RL, HL, FL or DLBCL (Table [2](#T2){ref-type="table"}). Most cases from the diagnostic classes examined in this study clustered distinctly together by hierarchical clustering, with the exception of DLBCL (Figure [1A](#F1){ref-type="fig"}). An accuracy rate of only 68.6% was achieved when the same profile of genes were tested on an independent test set (Table [2](#T2){ref-type="table"}).

###### 

The accuracy rates resulting from GEP classification of lymph node biopsies into selected subtypes.

  ---------------------------------------------------------------------------------------------------------------
  Comparison                Subtypes                  Optimal number\   Training set\       Test set\
                                                      of probes         accuracy rate (%)   accuracy rate\* (%)
  ------------------------- ------------------------- ----------------- ------------------- ---------------------
  **Global multi-class**    RL v cHL v FL v DLBCL     50                83.6                68.6

                                                                                            

  **Local binary-class**    RL v Lymphoma             130               87.7                80.0

                            cHL v NHL                 40                89.2                82.1

                            FL v DLBCL                10                84.8                76.1

                                                                                            

  **Global binary-class**   cHL v remaining cases     30                91.4                82.8

                            FL v remaining cases      60                82.7                88.5

                            DLBCL v remaining cases   490               87.7                82.8
  ---------------------------------------------------------------------------------------------------------------

\* The reported independent test set accuracy rates indicate the proportion of correctly classified cases from the total number assessed in the test datasets.

![**Hierarchical clustering of lymph node samples comparing distinct subtypes of lymphoma**. Heatmaps depict A. Multi-class analysis for cases of RL (grey, n = 16), cHL (black, n = 12), DLBCL (yellow, n = 8) and FL (magenta, n = 25); B. cHL (grey, n = 12) versus NHL (black, n = 53) and C. FL (grey, n = 25) versus DLBCL (black, n = 8). The columns represent the samples and rows represent the solicited genes. Each cell within the grid is indicative of the gene expression level for an individual sample with colour used to depict intensity on a graduating red (high) to green (low) scale. See Additional files [2](#S2){ref-type="supplementary-material"} and [3](#S3){ref-type="supplementary-material"} for the lists of top 10 and 20 classifier genes distinguishing HL from NHL and FL from DLBCL.](1755-8794-4-27-1){#F1}

Using local binary classification (lymphoma versus RL, cHL versus NHL, and FL v DLBCL groups; Table [2](#T2){ref-type="table"}) LOOCV accuracy rates at each independent comparison ranged from 84.8-89.2%. This high rate of accuracy was reflected in hierarchical clustering analysis, which showed only 5 samples (1 HL and 4 NHL) clustered incorrectly in the NHL versus HL comparison (Figure [1B](#F1){ref-type="fig"}), and a clear-cut separation between FL and DLBCL samples achieved using only 10 unique classifying genes (Figure [1C](#F1){ref-type="fig"}). Independent test set accuracy rates for these comparisons were all greater than 76% (Table [2](#T2){ref-type="table"}). See Additional files [2](#S2){ref-type="supplementary-material"} and [3](#S3){ref-type="supplementary-material"} for the lists of top 10 and 20 classifier genes distinguishing HL from NHL and FL from DLBCL.

Given the higher independent test set accuracy rates when only two defined types of diagnoses (classes) were considered in each analysis, we next investigated if we can diagnose a specific disease type compared to the remainder of all case types examined in this study. The gene classifiers, identified from this type of comparison are likely more specific to the disease type itself, as opposed to signature genes identified purely from a comparison of two subtypes. Samples were classified by comparing each subtype of lymphoma or RL to all remaining cases at the global level and accuracy rates for this type of binary classification determined. Based on varying optimal number of genes, LOOCV accuracy rates of training sets were all above 82%, with test set accuracy rates of 88.5%, 82.8%, 82.8% and 80.0% for FL, cHL, DLBCL and RL respectively.

Identified gene classifiers of RL, cHL, DLBCL and FL
----------------------------------------------------

Strong classifiers of reactive node tissue included the lower expression of a cohort of immune-response related genes compared to tissue diagnosed with lymphoma (Table [3](#T3){ref-type="table"}). Reduced expression in reactive node tissue was also observed for genes such as TATA box binding protein (TBP)-associated factor 140 kDa (*TAF3*) and Lim domain binding 2 (*LDB2*). Molecular classifiers identified for cases of cHL include the expression of a selection of chemokine ligands, and the transcription factor *STAT1*(Table [4](#T4){ref-type="table"}). The gene LIM domain only-2 (*LMO2*) was highly differentially expressed in FL compared to the remainder of cases examined (Table [5](#T5){ref-type="table"}) whilst high expression of cyclin-dependent kinase inhibitor 3 (*CDKN3*) transcripts was associated with DLBCL (Table [6](#T6){ref-type="table"}). A total of 31 genes within any of the four lists of genes identified from binary-class analyses are common to the 38 annotatable genes (of 50 probes) identified from our multi-class analysis. See Additional file [4](#S4){ref-type="supplementary-material"} for the complete list of classifiers (genes) for all classifications. The clustering of these identified classifiers is not influenced by clinical covariates such as the age or gender (Additional file [5](#S5){ref-type="supplementary-material"}).

###### 

Top 20 annotated classifier genes of RL samples.

  Accession number         Gene name                                                                             Symbol        Fold change
  ------------------------ ------------------------------------------------------------------------------------- ------------- -------------
  [AF126749](AF126749)     ATXN8 opposite strand (non-protein coding)                                            *ATXN8OS*     1.65
  [AL117661](AL117661)     TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140 kDa     *TAF3*        0.71
  [NM_006107](NM_006107)   LUC7-like 3 (S. cerevisiae)                                                           *LUC7L3*      0.68
  [AK025953](AK025953)     Myosin light chain kinase                                                             *MYLK*        0.55
  [NM_004367](NM_004367)   Chemokine (C-C motif) receptor 6                                                      *CCR6*        0.50
  [X64983](X64983)         Olfactory receptor, family 10, subfamily D, member 3 pseudogene                       *OR10D3P*     0.48
  [AK024040](AK024040)     Hypothetical LOC148413                                                                *LOC148413*   0.48
  [AF085877](AF085877)     Hypothetical protein LOC254100                                                        *LOC254100*   0.47
  [NM_001290](NM_001290)   LIM domain binding 2                                                                  *LDB2*        0.46
  [J02639](J02639)         Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5   *SERPINA5*    0.43
  [NM_002989](NM_002989)   Chemokine (C-C motif) ligand 21                                                       *CCL21*       0.42
  [X87888](X87888)         Immunoglobulin lambda locus                                                           *IGL@*        0.37
  [AF026932](AF026932)     Immunoglobulin lambda locus                                                           *IGL@*        0.37
  [AJ270695](AJ270695)     Basic helix-loop-helix family, member e41                                             *BHLHE41*     0.32
  [X87890](X87890)         Immunoglobulin lambda locus                                                           *IGL@*        0.31
  [U50342](U50342)         Immunoglobulin kappa constant                                                         *IGKC*        0.29
  [AF035799](AF035799)     Immunoglobulin kappa variable 3-20                                                    *IGKV3-20*    0.28
  [AF035787](AF035787)     Immunoglobulin heavy variable 3-48                                                    *IGHV3-48*    0.28
  [AF035035](AF035035)     Immunoglobulin kappa variable 1D-8                                                    *IGKV1D-8*    0.27
  [X57772](X57772)         Immunoglobulin lambda variable 6-57                                                   *IGLV6-57*    0.25

Genes are ranked from high to low fold change (differential expression in reactive versus remainder of samples).

###### 

The top 20 annotated classifier genes of cHL.

  Accession number         Gene name                                                                             Symbol       Fold change
  ------------------------ ------------------------------------------------------------------------------------- ------------ -------------
  [NM_006152](NM_006152)   Lymphoid-restricted membrane protein                                                  *LRMP*       2.83
  [NM_005582](NM_005582)   CD180 molecule                                                                        *CD180*      1.65
  [NM_002382](NM_002382)   MYC associated factor X                                                               *MAX*        0.65
  [NM_006564](NM_006564)   Chemokine (C-X-C motif) receptor 6                                                    *CXCR6*      0.57
  [NM_017458](NM_017458)   Major vault protein                                                                   *MVP*        0.55
  [NM_015364](NM_015364)   Lymphocyte antigen 96                                                                 *LY96*       0.52
  [D17028](D17028)         Prosaposin                                                                            *PSAP*       0.51
  [NM_000167](NM_000167)   Glycerol kinase                                                                       *GK*         0.51
  [NM_018664](NM_018664)   Basic leucine zipper transcription factor, ATF-like 3                                 *BATF3*      0.48
  [NM_006137](NM_006137)   CD7 molecule                                                                          *CD7*        0.45
  [NM_006018](NM_006018)   G protein-coupled receptor 109B                                                       *GPR109B*    0.43
  [NM_000579](NM_000579)   Chemokine (C-C motif) receptor 5                                                      *CCR5*       0.40
  [NM_003329](NM_003329)   Thioredoxin                                                                           *TXN*        0.36
  [M36693](M36693)         Superoxide dismutase 2, mitochondrial                                                 *SOD2*       0.34
  [NM_007315](NM_007315)   Signal transducer and activator of transcription 1, 91 kDa                            *STAT1*      0.34
  [M26123](M26123)         Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1   *SERPINA1*   0.33
  [NM_002258](NM_002258)   Killer cell lectin-like receptor subfamily B, member 1                                *KLRB1*      0.32
  [NM_002990](NM_002990)   Chemokine (C-C motif) ligand 22                                                       *CCL22*      0.29
  [NM_001276](NM_001276)   Chitinase 3-like 1 (cartilage glycoprotein-39)                                        *CHI3L1*     0.24
  [NM_002987](NM_002987)   Chemokine (C-C motif) ligand 17                                                       *CCL17*      0.18

Genes are ranked from high to low fold change (differential expression in cHL versus remainder of samples).

###### 

The top 20 annotated classifier genes of FL.

  Accession number         Gene name                                             Symbol       Fold change
  ------------------------ ----------------------------------------------------- ------------ -------------
  [NM_004244](NM_004244)   CD163 molecule                                        *CD163*      3.20
  [X57772](X57772)         Immunoglobulin lambda variable 6-57                   *IGLV6-57*   3.03
  [NM_005502](NM_005502)   ATP-binding cassette, sub-family A (ABC1), member 1   *ABCA1*      1.86
  [NM_005080](NM_005080)   X-box binding protein 1                               *XBP1*       1.86
  [NM_020397](NM_020397)   Calcium/calmodulin-dependent protein kinase ID        *CAMK1D*     1.83
  [NM_000153](NM_000153)   Galactosylceramidase                                  *GALC*       1.43
  [AF298812](AF298812)     Ectodysplasin A2 receptor                             *EDA2R*      0.72
  [NM_013340](NM_013340)   Protocadherin beta 1                                  *PCDHB1*     0.72
  [AB046800](AB046800)     Leucine rich repeat containing 4C                     *LRRC4C*     0.70
  [NM_016524](NM_016524)   Synaptotagmin XVII                                    *SYT17*      0.70
  [NM_005582](NM_005582)   CD180 molecule                                        *CD180*      0.69
  [NM_014212](NM_014212)   Homeobox C11                                          *HOXC11*     0.64
  [NM_014146](NM_014146)   Linker for activation of T cells family, member 2     *LAT2*       0.63
  [AK001057](AK001057)     Hypothetical LOC114130                                *MGC16384*   0.63
  [NM_006822](NM_006822)   RAB40B, member RAS oncogene family                    *RAB40B*     0.59
  [NM_002753](NM_002753)   Mitogen-activated protein kinase 10                   *MAPK10*     0.55
  [NM_000319](NM_000319)   Peroxisomal biogenesis factor 5                       *PEX5*       0.49
  [AB033107](AB033107)     Zinc finger protein 608                               *ZNF608*     0.46
  [NM_000869](NM_000869)   5-hydroxytryptamine (serotonin) receptor 3A           *HTR3A*      0.38
  [NM_005574](NM_005574)   LIM domain only 2 (rhombotin-like 1)                  *LMO2*       0.37

Genes are ranked from high to low fold change (differential expression in FL versus remainder of samples).

###### 

The top 20 annotated classifier genes of DLBCL.

  Accession number         Gene name                                                                                           Symbol      Fold change
  ------------------------ --------------------------------------------------------------------------------------------------- ----------- -------------
  [NM_000439](NM_000439)   Proprotein convertase subtilisin/kexin type 1                                                       *RBM16*     2.03
  [AF111846](AF111846)     Transcribed locus                                                                                   *CCNB1*     1.54
  [NM_000492](NM_000492)   Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)   *TFRC*      0.66
  [NM_017421](NM_017421)   Coenzyme Q3 homolog, methyltransferase (S. cerevisiae)                                              *SLC25A4*   0.65
  [AL137452](AL137452)     Protein arginine methyltransferase 10 (putative)                                                    *PGD*       0.63
  [NM_016138](NM_016138)   Coenzyme Q7 homolog, ubiquinone (yeast)                                                             *CDKN3*     0.63
  [NM_014726](NM_014726)   TBK1 binding protein 1                                                                              *CCT8*      0.63
  [AL049705](AL049705)     Mitochondrial ribosomal protein S14                                                                 *FKBP4*     0.61
  [NM_018320](NM_018320)   Ring finger protein 121                                                                             *BZW2*      0.61
  [NM_003566](NM_003566)   Early endosome antigen 1                                                                            *CCT3*      0.60
  [NM_006231](NM_006231)   Polymerase (DNA directed), epsilon                                                                  *GMPS*      0.56
  [NM_015902](NM_015902)   Ubiquitin protein ligase E3 component n-recognin 5                                                  *MSI1*      0.56
  [NM_002626](NM_002626)   Phosphofructokinase, liver                                                                          *MMRN1*     0.55
  [NM_001634](NM_001634)   Adenosylmethionine decarboxylase 1                                                                  *SLMAP*     0.55
  [NM_006476](NM_006476)   ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G                                  *NDUFV1*    0.53
  [NM_007159](NM_007159)   Sarcolemma associated protein                                                                       *SBNO1*     0.53
  [NM_006330](NM_006330)   Lysophospholipase I                                                                                 *ESPL1*     0.51
  [NM_003384](NM_003384)   Vaccinia related kinase 1                                                                           *MYO19*     0.49
  [NM_006585](NM_006585)   Chaperonin containing TCP1, subunit 8 (theta)                                                       *CYC1*      0.47
  [NM_001151](NM_001151)   Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4         *ANAPC5*    0.47

Genes are ranked from high to low fold change (differential expression in DLBCL versus remainder of samples).

Discussion
==========

In the present study, we used GEP microarrays to analyse 116 lymph node biopsies to assess the feasibility of this technology as a diagnostic tool in a clinical setting. This study is preceded by a significant body of research on GEP of lymphoma that has focused on understanding the pathogenesis of individual subtypes of lymphoma and refining the diagnosis and prognosis of these subtypes. However, our aim was to examine the practical question of whether GEP could be used to classify lymph node samples into the major subtypes of lymphoma and also to distinguish them from reactive lymph nodes.

The ability of GEP to diagnose biopsies of reactive, cHL, DLBCL and FL origin was examined with three strategies: global multi-class classification; local binary-class and global binary-class classification. The global multi-class approach classified each sample into one of the four diagnostic types with limited accuracy, which is known to decrease when more than two classes are considered simultaneously in linear classification algorithms \[[@B15]\]. Our binary comparisons, which compared a particular diagnostic type with either another type (local) or with the remainder of all cases (global), resulted in high (\>80%) accuracy rates for independent test sets, except when comparing FL to DLBCL (76.1%), the subtype that was most frequently misclassified. This limitation of GEP in classifying DLBCL may be related to the high degree of heterogeneity of the disease itself. Distinct molecular forms of DLBCL have been identified in other GEP studies \[[@B4],[@B16],[@B17]\], although this does not readily explain the misclassified cases of this study, which included both GCB and non-GCB DLBCL as judged by the Hans algorithm for immunohistochemistry. As the partial involvement of a tissue biopsy by lymphoma cannot be excluded, sampling error may also contribute to classification error rates. In regards to the comparison of RL with lymphoma, the two RL samples misclassified were both reactive hyperplasia. It should be noted that our reactive nodes were unselected and as such not all of which would necessarily have been B-cell predominant reactions. Therefore the random sampling of reactive nodes, which have different compartments, may contribute to sampling error. The accuracy to distinguish benign from malignant may be improved by increasing the number of cases used to build the classification, especially since there is an imbalance in the number of reactive biopsies (23) compared to the number of cancerous cases (93).

Application of our findings to clinical practice would require a much larger scale study to not only verify our identified genetic signature of particular types but also to assess the profile of uncommon lymphoma subtypes. We nonetheless feel that this work represents an important step in testing the principle of using GEP, based on simple and inexpensive arrays, as a diagnostic ancillary test for lymph node biopsy. We found that our laboratory practices were easily adapted to allow routine allocation of a portion of biopsy specimen for microarray as routine tests such as flow cytometry and cytogenetics, for diagnosis of lymphoma, also require fresh specimen (not formalin fixed). The development of new techniques such as quantitative nuclease protection assays on formalin-fixed, paraffin-embedded tissue blocks would overcome any difficulty in obtaining fresh tissue for microarray gene expression profiling and make GEP much more widely available even in small biopsies \[[@B18]\].

The 18% technical exclusion rate of samples arrayed in this study hampers the diagnostic utility of microarray. However, increased familiarity with the assay will reduce the exclusion rate, and in laboratories with a limited caseload, referral to a centralised service may be preferable. Given the substantial improvement of microarray technology since the initiation of this study, the use of newer genome-wide microarray platforms such as Illumina bead arrays would also improve the utility of this technology and contribute to reducing the technical exclusion rate seen in this study. Incorporation of microRNA array data \[[@B19]\] may also be appropriate, especially given the reported stability of microRNA expression \[[@B20]\].

In our study, 13 of the 40 classifier genes identified from a specific (local) comparison of cHL with NHL were also strong classifiers when cHL was globally compared to both NHL and reactive samples. This indicates that our classification strategy encompasses unique gene sets that can classify across more than two types of pathological conditions. Although some gene classifiers identified in our study were common to other reported GEP studies, the absence of some previously identified key classifiers may be due to variable probe make-up across different microarray platforms or resulting from differences in the type of diagnostic classes used in our classification compared to most published GEP studies \[[@B21]\]. Our distinct global binary comparisons would have likely identified gene signatures that represent the particular diagnostic type in question as it was compared to a mixture of lymphoma subtypes and non-cancerous samples.

The fact that high expression of *CD7*, *CCL17*and *STAT1*has been reported to be associated with cHL supports the reliability of our microarray data presented in this study \[[@B22]-[@B24]\]. As Hodgkin and Reed-Sternberg cells only account for on average 1% of the mixed cell types present in HL infiltrates, it is likely that the expression of some of the HL classifiers are derived from the stromal cell population. This should not influence the applicability of lymph node GEP to the diagnosis of HL given that this stromal reaction is likely to be similar across different HL samples and that their gene expression profiles have been reported to predict the outcome of HL \[[@B25]\]. Similarly for FL, our detected reduced expression of *CD163*, a macrophage marker, may reflect a low number of macrophages present in the node microenvironment in many cases of FL. The importance of this information is not diminished as increased reactive macrophages in a rare subset of FL have been reported to be associated with poorer survival \[[@B26]\]. *LMO2*, another strong molecular classifier identified for FL, has been reported to be expressed in approximately 50% of FL \[[@B27]\]. However, it is better known as a key gene expressed in GCB cell type of DLBCL \[[@B4]\] and as a strong predictor of superior outcome in DLBCL \[[@B28]\]. Given the importance of *LMO2*expression in DLBCL, its absence in our list of top 20 classifying genes of DLBCL may be due to the fact that only 5 cases examined (26%) are of GCB cell origin by immunohistochemistry. Instead, we have identified the gene cyclin D kinase inhibitor 3 (*CDKN3*), a known marker of the ABC-like DLBCL \[[@B29]\], to be expressed higher in our DLBCL samples compared to the other diagnostic types examined in this study.

The lower expression of several immunoglobulin genes in reactive node tissue may reflect the differences in the cellular makeup of the microenvironment of normal lymph node tissue compared to those diseased with lymphoma. Consistent with the phenotype of non-cancerous tissue, we detected reduced expressions of a potentially cancerous gene *TAF3*, a negative regulator of the tumour suppressor p53 \[[@B30]\].

Conclusions
===========

This proof of principle study has shown that microarray as a single platform assay can achieve reasonable diagnostic accuracy with the ability to differentiate lymphoma from non-cancerous reactive lymphadenopathy, and also classify three common subtypes of lymphoma. Molecular classifiers identified to be characteristic of each subtype examined could be combined onto a cost effective custom \'mini\' microarray to screen lymph node biopsies for expression profiles to assist the diagnosis of four common outcomes: reactive, cHL, FL or DLBCL in a relatively quick and inexpensive manner. Indeed the use of GEP as a diagnostic and prediction tool for other diseases is currently commercially available. One example includes the CupPrint and MammaPrint array service provided by Agendia for patients with breast cancer. The increased sensitivity in RNA extraction techniques has made GEP much more widely available even for paraffin sections, small fine needle aspiration and core biopsies, which are routinely used in a pathology lab. The application of GEP may streamline current diagnostic tests by allowing more selective use of costly and time consuming ancillary tests such as immunohistochemistry, immunophenotyping by flow cytometry, cytogenetics, FISH and PCR in every case of lymphoma. Its use may provide an objective diagnostic test that could be standardised across pathology laboratories.
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